The Venture Codex Logo

The Venture Codex

Parker Institute for Cancer Immunotherapy

1 Letterman Drive, Suite D3500, San Francisco, CA, 94129, United States

Overview

Coordinated cancer immunotherapy research to save lives.

Deals · 12mo

0

Links

WebsiteLinkedInX (Twitter)

Stage focus

Series A

Geographic focus

United Kingdom
United States

Sector focus

Health Care
Personal Health
Therapeutics

Investment portfolio

9rounds
NAMEDATESIZE
Dispatch Bio
Jul 2025Led
$216 MSeries A
ArsenalBio
Sep 2024Participated
$325 MSeries C
Georgiamune
Aug 2023Led
$75 MSeries A
Akamis Bio
Jan 2023Led
$30 MOther Equity
ArsenalBio
Sep 2022Participated
$220 MSeries B
Affini-T Therapeutics
Mar 2022Participated
$175 MOther Equity
ArsenalBio
Oct 2019Participated
$85 MSeries A
Tmunity Therapeutics
Jan 2018Participated
$100 MSeries A
ImaginAb
Oct 2017Participated
$8 MOther Equity
Dispatch Bio
Jul 2025Led
$216 MSeries A
ArsenalBio
Sep 2024Participated
$325 MSeries C
Georgiamune
Aug 2023Led
$75 MSeries A
Akamis Bio
Jan 2023Led
$30 MOther Equity
ArsenalBio
Sep 2022Participated
$220 MSeries B
Affini-T Therapeutics
Mar 2022Participated
$175 MOther Equity
ArsenalBio
Oct 2019Participated
$85 MSeries A
Tmunity Therapeutics
Jan 2018Participated
$100 MSeries A
ImaginAb
Oct 2017Participated
$8 MOther Equity
9
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Parker Institute for Cancer Immunotherapy: 9 funding rounds are recorded in the selected participation categories.All available history.
Parker Institute for Cancer Immunotherapy: 9 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series A22
Series B01
Series C+01
Other Equity12

Monthly Deal Activity

Parker Institute for Cancer Immunotherapy: 9 deals are recorded across 109 months.All available history.
Parker Institute for Cancer Immunotherapy: 9 deals are recorded across 109 months. All available history
MonthDeals
Oct '171
Nov '170
Dec '170
Jan '181
Feb '180
Mar '180
Apr '180
May '180
Jun '180
Jul '180
Aug '180
Sep '180
Oct '180
Nov '180
Dec '180
Jan '190
Feb '190
Mar '190
Apr '190
May '190
Jun '190
Jul '190
Aug '190
Sep '190
Oct '191
Nov '190
Dec '190
Jan '200
Feb '200
Mar '200
Apr '200
May '200
Jun '200
Jul '200
Aug '200
Sep '200
Oct '200
Nov '200
Dec '200
Jan '210
Feb '210
Mar '210
Apr '210
May '210
Jun '210
Jul '210
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '220
Feb '220
Mar '221
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '221
Oct '220
Nov '220
Dec '220
Jan '231
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '231
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '241
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '251
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Parker Institute for Cancer Immunotherapy: Health & Life Sciences is the largest displayed sector by deal count (9 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Parker Institute for Cancer Immunotherapy: Health & Life Sciences is the largest displayed sector by deal count (9 deals). All available history
SectorDeals
Health & Life Sciences9
Enterprise Software3
Manufacturing1

Deal Size Distribution

Parker Institute for Cancer Immunotherapy: 9 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Parker Institute for Cancer Immunotherapy: 9 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M1
$10M-$25M0
$25M-$50M1
$50M-$100M2
$100M-$250M4
$250M-$500M1
$500M-$1B0
$1B+0

Deals By Geography

Parker Institute for Cancer Immunotherapy: United States has the largest recorded deal count among the displayed regions (8 deals).All available history.

Top 2 of 2 regions; European countries are grouped as Europe.

Parker Institute for Cancer Immunotherapy: United States has the largest recorded deal count among the displayed regions (8 deals). All available history
RegionDeals
United States8
Europe1
Parker Institute for Cancer Immunotherapy: 20 co-investors are shown, with Westlake Village BioPartners sharing 4 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Parker Institute for Cancer Immunotherapy: 20 co-investors are shown, with Westlake Village BioPartners sharing 4 recorded deals. All available history
Co-investorShared deals
Westlake Village BioPartners4
Alexandria Venture Investments3
ARCH Venture Partners3
Bristol Myers Squibb3
Kleiner Perkins3
Byers Capital2
Catalio Capital Management2
Euclidean Capital2
Hitachi Ventures2
SoftBank2
University of California, San Francisco2
University of Pennsylvania2
Adage Capital Management1
Agent Capital1
Be The Match BioTherapies1
CJNV BioVenture1
Cycad Group1
dRx Capital1
Emerson Collective1
Erasca Ventures1

Investment Strategy

Parker Institute for Cancer Immunotherapy: Led accounts for 33% and participating for 67% of round participation.All available history.
Parker Institute for Cancer Immunotherapy: Led accounts for 33% and participating for 67% of round participation. All available history
CategoryDeals (count)Share (%)
Led333%
Participating667%
Parker Institute for Cancer Immunotherapy: Single-lead accounts for 0% and co-led for 100% of lead dynamics.All available history.
Parker Institute for Cancer Immunotherapy: Single-lead accounts for 0% and co-led for 100% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead00%
Co-led3100%

Team

Charles Michael Yim

Donor

Crystal Mackall

Director, Parker Institute for Cancer Immunotherapy at Stanford

Jeffrey Bluestone

President & CEO

John Connolly

PhD, Chief Scientific Officer

Karen Knudsen MBA PhD

Chief Executive Officer

Lewis Lanier

Director

Sean Parker

Founder and Chairman

Susan Schultz

Vice President of Business Operations